Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19

SE Sattui, JW Liew, ER Graef… - Expert Review of …, 2020 - Taylor & Francis
Introduction Several months into the COVID-19 pandemic, safe and effective treatments
against this global health disaster have yet to be identified. Clinical research trials around …

A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for COVID-19

AHJ Kim, JA Sparks, JW Liew, MS Putman… - Annals of internal …, 2020 - acpjournals.org
Hydroxychloroquine, an essential treatment for many patients with rheumatologic conditions,
has garnered widespread attention as a potential treatment for COVID-19 infection. The …

[HTML][HTML] Giant cell arteritis and COVID-19: similarities and discriminators. A systematic literature review

P Mehta, SE Sattui, KSM van der Geest… - The Journal of …, 2021 - jrheum.org
Objective. To identify shared and distinct features of giant cell arteritis (GCA) and
coronavirus disease 2019 (COVID-19) to reduce diagnostic errors that could cause delays in …

Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist

ER Graef, JW Liew, MS Putman, JF Simard… - Annals of the …, 2020 - ard.bmj.com
As of the end of March 2020, the COVID-19 pandemic has resulted in over 850 000
confirmed cases and an estimated 42 000 deaths worldwide. 1 All agree that safe and …

Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a …

SE Sattui, R Conway, MS Putman, AM Seet… - The Lancet …, 2021 - thelancet.com
Background Patients with primary systemic vasculitis or polymyalgia rheumatica might be at
a high risk for poor COVID-19 outcomes due to the treatments used, the potential organ …

Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine …

M DiIorio, K Kennedy, JW Liew, MS Putman… - RMD open, 2022 - rmdopen.bmj.com
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28
days or longer, among people with systemic autoimmune rheumatic diseases (SARDs) …

Immediate effect of the COVID-19 pandemic on patient health, health-care use, and behaviours: results from an international survey of people with rheumatic diseases

JS Hausmann, K Kennedy, JF Simard… - The Lancet …, 2021 - thelancet.com
Background The impact and consequences of the COVID-19 pandemic on people with
rheumatic disease are unclear. We developed the COVID-19 Global Rheumatology Alliance …

Industry payments to practicing US rheumatologists, 2014–2019

MS Putman, JE Goldsher, CS Crowson… - Arthritis & …, 2021 - Wiley Online Library
Objective Payments from the pharmaceutical industry to practicing physicians may influence
prescribing behavior. This study was undertaken to investigate the nature, quantity, and …

Myositis-associated interstitial lung disease: predictors of failure of conventional treatment and response to tacrolimus in a US cohort

N Sharma, MS Putman, R Vij, ME Strek… - The Journal of …, 2017 - jrheum.org
Objective. Patients with myositis-associated interstitial lung disease (MA-ILD) are often
refractory to conventional treatment, and predicting their response to therapy is challenging …

[HTML][HTML] Intentional sedation to unconsciousness at the end of life: findings from a national physician survey

MS Putman, JD Yoon, KA Rasinski, FA Curlin - Journal of Pain and …, 2013 - Elsevier
Context The terms “palliative sedation” and “terminal sedation” have been used to refer to
both proportionate palliative sedation, in which unconsciousness is a foreseen but …